Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients (MAGNA VICTORIA)

This study has been completed.
Sponsor:
Collaborator:
Novo Nordisk A/S
Information provided by (Responsible Party):
M.B. Bizino, MD, principal investigator, Leiden University Medical Center
ClinicalTrials.gov Identifier:
NCT01761318
First received: December 20, 2012
Last updated: May 4, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)